<?xml version="1.0" encoding="UTF-8"?>
<p class="p">Different regulatory effects might be obtained when targeting plasma membrane for therapy (
 <xref ref-type="fig" rid="ijms-20-02167-f005" class="xref">Figure 5</xref>):
 <list list-type="bullet" class="list">
  <list-item class="list-item">
   <p class="p">Direct regulation through membrane structure modification: Dietary lipids and environmental changes modify cell membranes changing their properties and microdomain organization, thus controlling the localization and activity of proteins such as G proteins (interaction with membrane and downstream signaling) [
    <xref rid="B199-ijms-20-02167" ref-type="bibr" class="xref">199</xref>,
    <xref rid="B200-ijms-20-02167" ref-type="bibr" class="xref">200</xref>], the transcription of proteins involved in stress response such as heat shock proteins (Hsp) [
    <xref rid="B201-ijms-20-02167" ref-type="bibr" class="xref">201</xref>], or the production of second messengers such as Cer [
    <xref rid="B202-ijms-20-02167" ref-type="bibr" class="xref">202</xref>]. Thus, MUFA treatments can change the order of Lo and Ld microdomains.
   </p>
  </list-item>
  <list-item class="list-item">
   <p class="p">Regulation of enzymatic activity to alter membrane lipid levels: Enzymatic activity of SMS and other enzymes from SL metabolism are altered in cancer and consequently modify membrane composition and structure. Hydroxyl-C18 unsaturated fatty acids (hydroxyoleic, hydroxilinoleic, hydroxy-α-linolenic and hydroxy-γ-linolenic acids) have effects on SMS activity [
    <xref rid="B138-ijms-20-02167" ref-type="bibr" class="xref">138</xref>].
   </p>
  </list-item>
  <list-item class="list-item">
   <p class="p">Modification of gene expression that results in alterations of membrane lipid composition: this gene expression change might affect the activity of an enzyme, protein-lipid interactions or protein-protein interaction. DNA-associated PL are found in nuclear membrane [
    <xref rid="B203-ijms-20-02167" ref-type="bibr" class="xref">203</xref>] and their effects on nuclear functions have been documented [
    <xref rid="B103-ijms-20-02167" ref-type="bibr" class="xref">103</xref>]. Evidence of this type of MLT include the increased SM levels in differentiated cells in contrast to low levels of this lipid on proliferating cells [
    <xref rid="B138-ijms-20-02167" ref-type="bibr" class="xref">138</xref>]. This increase does not take place with SM addition but for SMS increased activity [
    <xref rid="B138-ijms-20-02167" ref-type="bibr" class="xref">138</xref>,
    <xref rid="B139-ijms-20-02167" ref-type="bibr" class="xref">139</xref>], which supports the concept of MLT-induced gene expression alteration.
   </p>
  </list-item>
  <list-item class="list-item">
   <p class="p">Lipid alterations that affect protein-protein interactions in specific membrane microdomains: The alteration of lipid ratios or the presence of particular lipids in membranes cause changes in protein-protein interactions. For example, low PtdEtn/SM ratios reduce Ras interactions both with membrane components and with downstream partners, in turn, inhibiting the transduction through proliferative signaling cascades and preventing proliferation in cancer cells [
    <xref rid="B139-ijms-20-02167" ref-type="bibr" class="xref">139</xref>].
   </p>
  </list-item>
  <list-item class="list-item">
   <p class="p">Direct MLT-drug binding to a protein that alters its membrane binding affinity or that of other signaling proteins: In that case, the MLT formulated molecule binds to a protein rather than a lipid. This is the case of prenylation inhibitors, which prevent Ras from binding to membrane and subsequently inhibit cancer cell proliferation while inducing cell differentiation and cell death [
    <xref rid="B139-ijms-20-02167" ref-type="bibr" class="xref">139</xref>].
   </p>
  </list-item>
 </list>
</p>
